Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30038589 | 0.81 | HSD11B1 (0.49) | HSD11B1LMNAHTTKMT2ATDP1 | |
| SCHEMBL25736043 | 0.80 | KMT2A (0.56) | HSD11B1LMNAHTTKMT2ATDP1 | |
| SCHEMBL8525250 | 0.78 | HSD11B1 (0.59) | HSD11B1LMNAHTTKMT2ANR1I2 | |
| SCHEMBL11879975 | 0.78 | CA12 (0.51) | HSD11B1LMNAHTTKMT2ACNR2 | |
| SCHEMBL30309104 | 0.74 | POLB (0.47) | HSD11B1LMNAHTTKMT2ATDP1 | |
| SCHEMBL28877353 | 0.74 | KMT2A (0.46) | HSD11B1LMNAHTTKMT2ATDP1 | |
| SCHEMBL11511069 | 0.71 | KDM4E (0.46) | HSD11B1KMT2ATDP1CA12CA1 | |
| SCHEMBL28008307 | 0.71 | KMT2A (0.43) | HSD11B1LMNAKMT2ATDP1L3MBTL1 | |
| SCHEMBL25702587 | 0.70 | KMT2A (0.53) | HSD11B1KMT2ATDP1NR1I2 | |
| SCHEMBL10896740 | 0.70 | TDP1 (0.52) | HSD11B1LMNAHTTKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2877457-A1 | CYSTATHIONINE- -LYASE (CSE) INHIBITORS | Sova Pharmaceuticals, Inc. (US) | 2015-06-03 | — | — | EP | disclosed |
| EP-2877175-A2 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | Sova Pharmaceuticals, Inc. (US) | 2015-06-03 | — | — | EP | disclosed |
| WO-2014018570-A1 | CYSTATHIONINE-Υ-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014018571-A2 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | SOVA PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| US-4153710-A | HYPOGLYCEMIC AGENTS | STAROGARDZKIE ZAKLADY FARMACEUTYCZNE POLFA (PL) | 1979-05-08 | — | — | US | disclosed |
| US-3932658-A | Composition and method for lower blood sugar containing N-[4-(β-<2-methoxy-5-chloro-benzamido>-ethyl)-benzenesulfonyl]-N'-cyclopentyl-urea | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-01-13 | — | — | US | disclosed |